Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study.
Author(s): Duranay M, Kanbay M, Akay H, Unverdi S, Surer H, Altay M, Kirbas I, Covic A, Zoccali C
Affiliation(s): Department of Nephrology, Ankara Educational and Research Hospital, Ankara, Turkey.
Publication date & source: 2010, Nephron Clin Pract., 114(3):c213-7. Epub 2009 Nov 28.
Publication type: Randomized Controlled Trial
Renal artery stenosis (RAS) is a progressive disease and may lead to chronic kidney disease by deterioration of renal functions. Endothelial dysfunction is an important causative factor for kidney damage after RAS revascularization. Nebivolol, a new generation beta blocker induces endothelium-related arterial relaxation by nitric oxide (NO) and may improve endothelial dysfunction. This pilot study tested the effect of nebivolol on the glomerular filtration rate (GFR) in a series of 33 patients with severe RAS (>70%) who underwent revascularization. After revascularization, nebivolol was added to antihypertensive treatment in 17 randomly selected patients while 16 patients (control group) continued their standard treatment. Estimated glomerular filtration rate (eGFR), proteinuria as well as nitrite and nitrate levels were measured at baseline and 6 months after the revascularization procedure. Six months after revascularization, eGFR increased from 44.8 to 50.6 ml/min in the nebivolol group. In contrast, eGFR did not change in the control group. Nitrite/nitrate levels decreased to a significant extent both in the nebivolol and in the control group. Proteinuria decreased more in the nebivolol group compared to the control group. These pilot data support a full-fledged clinical trial, testing whether nebivolol may be beneficial in the post-revascularization phase in patients with RAS. Copyright 2009 S. Karger AG, Basel.